keynote-355: pembrolizumab in triple-negative breast cancer
Published 4 years ago • 2.8K plays • Length 2:07Download video MP4
Download video MP3
Similar videos
-
1:30
keynote-355: hrqol unaffected by the addition of pembrolizumab to chemotherapy for tnbc
-
4:49
keynote-355: pembro chemo in triple-negative breast cancer
-
4:11
immunotherapy for tnbc: impassion130 & keynote-355
-
2:34
esmo 2021 breast cancer highlights: tulip and keynote-355
-
12:45
keynote-355: first-line pembrolizumab plus chemotherapy for metastatic triple-negative breast ca...
-
2:24
keynote-355: pembrolizumab in triple-negative breast cancer
-
2:00
pembrolizumab plus chemotherapy show efficacy for tnbc in keynote-355
-
4:20
keynote-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer
-
1:42
the case for neoadjuvant pembrolizumab in tnbc
-
1:39
encouraging developments in triple negative breast cancer immunotherapy
-
4:01
keynote-355: outcomes in pts discontinuing chemo before pembro and in pts with immune-mediated aes
-
3:18
#esmo21 highlights on combination of pembrolizumab plus chemotherapy in mtnbc: the keynote-355 study
-
4:11
asco 2020: pembrolizumab plus chemotherapy for patients with metastatic triple-negative breast c...
-
3:07
highlights from sabcs 2021: t-dxd, keynote-355, pada-1 & emerald
-
1:35
longer overall survival in metastatic tnbc with pembrolizumab - medpage today
-
1:03
new directions in immunotherapy for improving outcomes in tnbc
-
4:53
chemoimmunotherapy in tnbc: the keynote-355 trial
-
4:20
keynote 522: pembrolizumab as neoadjuvant treatment for early tnbc
-
0:43
management of residual disease in triple negative breast cancer